Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899104 · ClinicalTrials.gov registry record
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
A clinical trial of Prostatic Neoplasms, Castration-Resistant, sponsored by Bayer.
- Completed
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT02899104: Completed study of Prostatic Neoplasms, Castration-Resistant, sponsored by Bayer.
NCT02899104 is a study of Prostatic Neoplasms, Castration-Resistant that has completed, run by Bayer. The registered enrollment target is 200 participants, below the 721-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02899104, a study of Prostatic Neoplasms, Castration-Resistant, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
Primary Outcome
The treating physician should select out of the following options: Prostate Specific Antigen rising, Alkaline phosphatase (ALP) , Lactate dehydrogenase (LHD), testosterone, pain, symptoms, bone lesions, disease progression.
Conditions Studied
Interventions
- DRUG Xofigo (Radium-223 dichloride, BAY88-8223)
Study Locations (1)
New Jersey
- Whippany - Whippany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-06-15 |
| Est. Completion | 2019-03-31 |
What the finished NCT02899104 record still lists
NCT02899104 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 721-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Prostatic Neoplasms, Castration-Resistant appearing as the primary indexed condition, and to 1 intervention - of which Xofigo (Radium-223 dichloride, BAY88-8223) is the first listed.
NCT02899104 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02899104 about?
NCT02899104 is a clinical study titled "Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )". Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
What is the current status of trial NCT02899104?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2017-06-15. Estimated completion is 2019-03-31.
What conditions does trial NCT02899104 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Castration-Resistant.
What interventions are being tested in trial NCT02899104?
The interventions under investigation include: Xofigo (Radium-223 dichloride, BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT02899104?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02899104 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms, Castration-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02899104's enrollment target sits among peer trials
200 5th of 10 higher than 6 of 10 other Prostatic Neoplasms, Castration-Resistant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms, Castration-Resistant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
RECRUITING · Phase 1
-
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RECRUITING · Phase 1
-
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RECRUITING · Phase 4
-
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 3
-
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI